NEW YORK (GenomeWeb News) – Epigenomics today announced Companion Dx Reference Labs has obtained the rights to establish and commercialize a colorectal cancer test using the methylated Septin9 biomarker.

Under the terms of the deal, Companion Dx will be able to use Epigenomics' biomarker to create a blood-based, laboratory developed test, while Epigenomics is entitled to double-digit royalties on sales of the test. Other terms of the agreement were not disclosed.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PNAS this week: co-evolutionary signatures of insect hosts and bacterial symbionts, distinct transcript isoforms of high-grade ovarian cancer, and more.

Adam Rutherford discusses genetic genealogy at the Guardian.

Portions of the US 21st Century Cures Act are raising some safety concerns.

David Dobbs writes at Buzzfeed that genomics has delivered little on its promises.